Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV T Cell Immunity Panel to Guide Valganciclovir Prophylaxis in Lung Transplant Recipients
NCT05708755Phase 2Recruiting
- Sponsor
- NYU Langone Health
- Start
- Sep 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of valganciclovir in cytomegalovirus infection (CMV), sponsored by NYU Langone Health. Started Sep 2024; status: recruiting.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT05708755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05708755.